Equities researchers at Wedbush lifted their target price on shares of GTx (NASDAQ: GTXI) from $6.00 to $9.00 in a research report issued on Monday, Analyst Ratings Network reports. The firm currently has an “outperform” rating on the stock. Wedbush’s target price would suggest a potential upside of 28.57% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of GTx in a research note to investors on Thursday. They now have a $8.00 price target on the stock, up previously from $6.00. Analysts at Stifel Nicolaus initiated coverage on shares of GTx in a research note to investors on Friday, April 5th. They set a “buy” rating and a $7.00 price target on the stock.
GTx (NASDAQ: GTXI) traded up 4.95% on Monday, hitting $7.00. GTx has a 52-week low of $2.62 and a 52-week high of $5.41. The stock’s 50-day moving average is currently $4.37. The company’s market cap is $440.6 million.
GTx (NASDAQ: GTXI) last issued its quarterly earnings data on Friday, May 3rd. The company reported ($0.20) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.21) by $0.01. During the same quarter in the prior year, the company posted ($0.18) earnings per share. The company’s quarterly revenue was down 100.0% on a year-over-year basis. On average, analysts predict that GTx will post $-0.83 earnings per share for the current fiscal year.
GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that targets hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions.